This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Individuals with atopic dermatitis are susceptible to servere and prolonged viral infections of the skin. Most significantly, they are predisposed to a life-threatening disease known as eczema vaccinatum that follows immunization with the smallpox vaccine or close contact with someone who recently received the vaccine. The propensity to exzema vaccinatum is life-long, not sparing individuals with atopic dermatitis that appears to have resolved. This will be an unblinded, single-center, 8-week pilot study of healthy adults carried out at National Jewish Medical and Research Center. The primary objectives are to determine whether immune responses are provoked by the administration of KLH, a harmless bilogical substance to which people are not exposed outside of clinical studies, and to determine the safety of administering KLH by a method identical to that used for smallpox vaccination. This study is needed to establish a stand-in for smallpox vaccination in clinical studies.
Showing the most recent 10 out of 1065 publications